Category :hjmevxhh

first_img Share Quindell share price plummets as confusion over share dealings reigns whatsapp Monday 10 November 2014 8:24 pm whatsapp Oliver Smith Show Comments ▼ More From Our Partners Police Capture Elusive Tiger Poacher After 20 Years of Pursuing the Huntergoodnewsnetwork.orgA ProPublica investigation has caused outrage in the U.S. this weekvaluewalk.comBrave 7-Year-old Boy Swims an Hour to Rescue His Dad and Little Sistergoodnewsnetwork.orgUK teen died on school trip after teachers allegedly refused her pleasnypost.comAstounding Fossil Discovery in California After Man Looks Closelygoodnewsnetwork.orgBiden received funds from top Russia lobbyist before Nord Stream 2 giveawaynypost.comRussell Wilson, AOC among many voicing support for Naomi Osakacbsnews.comKiller drone ‘hunted down a human target’ without being told tonypost.comNative American Tribe Gets Back Sacred Island Taken 160 Years Agogoodnewsnetwork.orgSupermodel Anne Vyalitsyna claims income drop, pushes for child supportnypost.comInside Ashton Kutcher and Mila Kunis’ not-so-average farmhouse estatenypost.comFeds seized 18 devices from Rudy Giuliani and his employees in April raidnypost.comFlorida woman allegedly crashes children’s birthday party, rapes teennypost.comKamala Harris keeps list of reporters who don’t ‘understand’ her: reportnypost.com‘Neighbor from hell’ faces new charges after scaring off home buyersnypost.comI blew off Adam Sandler 22 years ago — and it’s my biggest regretnypost.com980-foot skyscraper sways in China, prompting panic and evacuationsnypost.comPuffer fish snaps a selfie with lucky divernypost.com Tags: Quindell Confusion surrounding the convoluted share dealings of three of Quindell’s largest individual shareholders caused havoc for the price of the insurance outsourcer. Last Wednesday, Quindell said its chairman, finance chief and a non-executive director had entered into a loan facility to borrow £8.76m, secured against their own shares, in order to fund the purchase of £2.2m more Quindell stock. The move led to confusion over the weekend about the terms of the loan had been made. Quindell yesterday issued a statement to clarify the transaction. “As previously stated and as demonstrated by the initial purchases made by the purchasing directors and the fact that the majority of the board has acquired shares recently, we believe the current market valuation of the company is materially below its true value,” chairman Rob Terry said yesterday. The three directors have agreed to buy back shares transferred to EFH in two years’ time “at a price equal to 69pc of the three-day average market value per share applicable at the date of entering into the facility, less margin calls paid”. The firm is required to deliver the transferred shares or equivalent shares to each purchasing director on payment”. Quindell’s shares plummeted 19.83 per cent to close at 95p. DIRECTOR’S SHARE DEALINGS EXPLAINED Quindell’s chairman Rob Terry controlled 45.65m shares in the company, around 10.5 per cent, prior to the two-year “sale and repurchase agreement” announced last week. Terry then transferred 8.85m shares over to Equities First Holdings, a securities based lender, and received £7.47m in return – an average price of just 84.5p, a nearly 30 per cent discount to Quindell’s share price last week. He used the funds generated to buy another 1m shares in Quindell at market price, giving him a total interest of around 46.65m shares in the company. While yesterday’s statement makes it clear that “EFH… is under no obligation to hold or retain the transferred shares,” Terry said “each of us purchasing directors relied upon assurances from EFH that… the shares transferred would not be disposed of outright.” Similarly Quindell’s finance chief Laurence Moorse sold 200,000 shares to EFH for £168,714 and reinvested £62,000 in stock, and non-executive director Steve Scott sold 5.11m shares for £1.1m and reinvested £873,000 in Quindell stock. If Quindell’s stock falls more than 20 per cent below the value at which they were transferred to EFH, around 68p, then the three directors will be liable to put up additional stock or cash as collateral on the loans.  last_img read more

first_img Rep. Diana DeGette (D-Colo.), chair of the House Energy and Commerce Committee’s oversight and investigations panel. Pablo Martinez Monsivais/AP What’s included? Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+. First 30 days free. GET STARTED GET STARTED WASHINGTON — Executives from Pfizer, Moderna, Johnson & Johnson, AstraZeneca, and Novavax will testify Tuesday before the House Energy and Commerce Committee’s oversight arm. The hearing, titled “Pathway to Protection: Expanding Availability of COVID-19 Vaccines,” will give lawmakers a chance to grill drug makers on why supply of Covid-19 vaccines is still so limited — and what they’re doing to fix it.Here are a few of the burning questions STAT hopes lawmakers will ask. What is it? STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond. Nicholas Florko Log In | Learn More Politics center_img [email protected] Tags CongressCoronaviruspolicySTAT+Vaccines Washington Correspondent Nicholas Florko reports on the the intersection of politics and health policy. He is the author the newsletter “D.C. Diagnosis.” By Nicholas Florko Feb. 23, 2021 Reprints The questions Congress should ask Pfizer, Moderna, and Johnson & Johnson about the Covid-19 vaccines  Daily reporting and analysis The most comprehensive industry coverage from a powerhouse team of reporters Subscriber-only newsletters Daily newsletters to brief you on the most important industry news of the day STAT+ Conversations Weekly opportunities to engage with our reporters and leading industry experts in live video conversations Exclusive industry events Premium access to subscriber-only networking events around the country The best reporters in the industry The most trusted and well-connected newsroom in the health care industry And much more Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr. About the Author Reprints @NicholasFlorko last_img read more

first_imgAdvertisementOUP said its lexicographers regularly review entries to make sure they’re accurate. This time the voice of the people helped create change, a spokesperson said in an email Monday.“Sometimes the team focus on topics highlighted by user feedback [such as last year’s petition about the definition of ‘woman’] and sometimes these topics are driven by current events or through projects taking place within the Oxford Languages team,” the spokeswoman wrote.She cited work the organization has done on words relating to race, racial diversity and the use of “they” as a pronoun for nonbinary people as other examples this year. Celebrity defense attorney F. Lee Bailey, who defended O.J. Simpson, died at 87 June 5, 2021 AdvertisementDC Young Fly knocks out heckler (video) – Rolling OutRead more6 comments’Mortal Kombat’ Exceeded Expectations Says WarnerMedia ExecutiveRead more2 commentsDo You Remember Bob’s Big Boy?Read more1 commentsKISS Front Man Paul Stanley Reveals This Is The End Of KISS As A Touring Band, For RealRead more1 comments Advertisement OXFORD, ENG. (CNN) – Earlier this year, Oxford University Press changed its entry for “woman” in its dictionaries, including the Oxford English Dictionary, to include more positive ways to describe a female. “We have expanded the dictionary coverage of ‘woman’ with more examples and idiomatic phrases which depict women in a positive and active manner,” according to a statement from OUP. “We have ensured that offensive synonyms or senses are clearly labeled as such and only included where we have evidence of real world usage.”Phrases like “woman of the moment” were added to equal the old saying of the “man of the moment.” In addition, one of the definitions of “woman” now refers to a “person’s wife, girlfriend or female lover” as opposed to being tied to only a man.The definition of “man” was also updated to include gender-neutral terms and references to “sexual attractiveness or activity” were changed for “man” and “woman” entries. New York attorney general’s office confirms criminal investigation of Trump Organization May 19, 2021 Latest Dictionary.com update includes words & phrases related to race & identity March 12, 2021 Lexicographers reviewed samples in its dictionary data to make sure representations of woman were “positive and active,” according to the organization.The review looked at the definitions of “man” and “woman,” as well as examples of the word being used in a sentence, labels and synonyms. It also looked at entries that are associated with women.Labels were then added to “offensive, derogatory, or dated” terms. The synonyms were also evaluated to make sure they’re genuine synonyms. The synonyms for “woman” had listed “wench,” “piece” and other derogatory terms last year. Some of those synonyms in the OED were removed and others have a label, such as the the word “bitch” being an offensive one.The definition of “housework” was also updated to take gender out of the equation in the dictionaries. “She still does all the housework,” was changed to “I was busy doing housework when the doorbell rang.”The organization said all of this is part of the ongoing effort to “re-examine” language and labeling to make sure it’s up to date for a “modern audience.” The-CNN-Wire™ & © 2020 Cable News Network, Inc., a WarnerMedia Company. All rights reserved. RELATEDTOPICS AdvertisementRecommended ArticlesBrie Larson Reportedly Replacing Robert Downey Jr. As The Face Of The MCURead more81 commentsGal Gadot Reportedly Being Recast As Wonder Woman For The FlashRead more29 comments AdvertisementTags: cnndictionary Advertisement Websites, apps globally hit by major internet outage June 9, 2021last_img read more

first_img4:40 p.m.Rescue crews are on the scene of a rollover crash just north of the Luckett Road exit ramp on Southbound I-75. Expect delays. Advertisement Traffic Alerts: May 21 May 23, 2021 AdvertisementTags: traffic RELATEDTOPICS Advertisement7:42 a.m.Burnt Store Road is shut down just north of Kismet Parkway West due to a crash involving a vehicle and a bicyclist with serious injuries. Please avoid the area and seek alternate routes as crash investigators respond to the scene. 1:05 p.m.The northbound lanes of Del Prado Boulevard South near Viscaya Parkway are down to one lane due to a crash. Avoid the area, and seek an alternate route for the next one to two hours. Traffic Alerts: May 25 May 26, 2021 Traffic Alerts: May 24 May 25, 2021 AdvertisementRecommended ArticlesBrie Larson Reportedly Replacing Robert Downey Jr. As The Face Of The MCURead more81 commentsGal Gadot Reportedly Being Recast As Wonder Woman For The FlashRead more29 comments Future developments cause new Colonial congestion concerns June 10, 2021 AdvertisementDC Young Fly knocks out heckler (video) – Rolling OutRead more6 comments’Mortal Kombat’ Exceeded Expectations Says WarnerMedia ExecutiveRead more2 commentsDo You Remember Bob’s Big Boy?Read more1 commentsKISS Front Man Paul Stanley Reveals This Is The End Of KISS As A Touring Band, For RealRead more1 comments Advertisementlast_img read more

Mouth mechanic turned market manipulator The Alberta Securities Commission (ASC) has reciprocated orders imposed by the British Columbia Securities Commission (BCSC) against Myron Sullivan II (a.k.a Fred Myron George Sullivan), Global Response Group (GRG) Corp., and IMC-International Marketing of Canada Corp. An ASC panel ordered, among other things, that Sullivan, Global Response Group, and IMC-International Marketing of Canada be permanently banned from trading in or purchasing securities, acting as a registrant or promoter, and disseminating to the public any oral or written communications, by or on behalf of any issuer, that promote or reasonably could be expected to promote the purchase or sale of securities of such issuer. The ASC panel also ordered that all trading in or purchasing of Global Response Group and IMC-International Marketing of Canada securities must permanently cease. The BCSC found that the named parties illegally distributed securities, Sullivan knowingly made untrue statements while promoting Global Response Group, and Sullivan and Global Response Group perpetrated a fraud on investors. OSC to consider reciprocating BCSC orders The ASC panel stated that “the evidence is that Alberta residents were among the affected investors. This indicates that the misconduct crossed provincial boundaries – an example of the sort of circumstance that the reciprocation power was designed to address.” PwC alleges deleted emails, unusual transactions in Bridging Finance case Share this article and your comments with peers on social media Keywords EnforcementCompanies Alberta Securities Commission BFI investors plead for firm’s sale IE Staff Facebook LinkedIn Twitter Related news read more

first_imgRelated15 from Middlesex Receive Governor-General Awards Advertisements Related15 from Middlesex Receive Governor-General Awards FacebookTwitterWhatsAppEmail Fifteen residents of the county of Middlesex have been presented with Governor-General’s awards in recognition of their contribution to the development of their parishes.The Governor-General’s Achievement Awards was presented to five persons, who have emerged from humble beginnings to assume leadership roles in their communities, while 10 young people received the Governor-General’s Youth Awards for Excellence, in recognition of their voluntary service.At a function held recently at the Runaway Bay HEART Hotel in St. Ann, Governor-General, His Excellency the Most Hon. Professor Kenneth O. Hall, presented plaques to the 15 Jamaicans in recognition of their invaluable contribution to society and for their outstanding achievements.“I wish to congratulate all the awardees and especially those who are receiving today, but also past awardees, who have dedicated themselves and have impacted their communities throughout this country,” he said.The Governor-General noted that the awards scheme has played a pivotal role in recognizing and encouraging the spirit of volunteerism and excellence in the country. “I am confident that this vision of excellence will be achieved as we bring together Jamaicans of all generations to use their range of skills and talents to build Jamaica, land we love,” he stated.The Governor-General further paid tribute to his predecessor, “who launched this programme and nurtured it so I am able not only to share in it, but really to revel in its success”.The awardees are: Edith May Thomas, an educator from the parish of Clarendon; Rev. Owen Gordon, a Justice of the Peace and social worker from Manchester; Calvin Powell, founder of Zion Roots of St. Catherine; Jeffrey McKitty from St. Mary, who is general manager of Beaches Boscobel; and Pixley Irons, a Justice of the Peace and businessman from St. Ann.The 10 young awardees comprise: Clayton McCalla and Renee Miller from Clarendon; Angelique Davidson and Bryan Wallace from Manchester; Shannon Gobourne and Kirk Abrahams from St. Catherine; Shakera Blake and Ryan Bryan from St. Mary and Jennifer Brown-Cunningham and Cieanna Thasa Smith from St. Ann.Mr. Irons, in his remarks, expressed gratitude for the national recognition and pledged to “continue to play our part as good citizens of Jamaica and will be true to ourselves, our fellowmen and our Lord”.Meanwhile, Cieanna told JIS News that she was very proud to be one of the recipients. She encouraged other young persons across the island to hold fast to their dreams and work very hard in order to succeed in life.“I must say that without confidence, you are twice defeated in the race of life. It is not easy when you are on the road to success, there will always be disappointments that you will face, but you have to keep your objectives and your goals in mind in order to achieve,” she said.The award programme is sponsored by the Gleaner Company Limited, Jamaica National Building Society (JNBS), Victoria Mutual Building Society (VMBS), First Caribbean International Building Society and Scotia Jamaica Building Society.center_img Related15 from Middlesex Receive Governor-General Awards 15 from Middlesex Receive Governor-General Awards UncategorizedJuly 31, 2006last_img read more

first_imgPress Briefing by White House COVID-19 Response Team and Public Health Officials 23 February The White HouseVia Teleconference3:05 P.M. ESTACTING ADMINISTRATOR SLAVITT: I’m starting today on a solemn note as we’re nearing 500,000 Americans who’ve lost their lives from COVID-19. To mark this grim milestone, this evening, the President and First Lady, along with the Vice President and Second Gentleman, will hold a moment of silence in a ceremony at sundown to honor those who have lost their lives to this pandemic.Everyone lost is someone whose life and gifts were cut short. Our hearts go out to all of those who are grieving loved ones who are so deeply missed.For those of us in the administration, the occasion makes us more determined to turn the tide on COVID-19 so the losses can subside and the healing can begin. The President has asked us to use every possible resource to make that happen.On Friday, I provided an overview of how the extreme weather had impacted our vaccination efforts. And today, I want to give an update on our progress to recover. That progress began as soon as the weather began to improve, thanks to an all-out, round-the-clock effort from our teams and partners.McKesson ran extended shifts Saturday and Sunday to pack vaccines, and members of the military joined them in their efforts. Seventy McKesson employees volunteered to work 1:00 a.m. shifts Saturday night, Sunday morning to prepare shipments to meet an 11:00 a.m. transit deadline. On Sunday, UPS extended its onsite trailer time at the McKesson facility in Kentucky to allow them to pack hundreds of thousands more doses.Thanks to that and many more, those efforts, today alone, we plan to deliver 7 million doses.This is a combination of catch-up from last week’s doses that were delayed from the weather and doses going out as a normal part of today’s normal distribution.I reported on Friday that we would catch up on deliveries by the end of this week. We now anticipate that all backlog doses will be delivered by midweek.But delivering doses to administration sites is, as we know, only the first step. Sites around the country have a significant job ahead of them to quickly vaccinate the public. It will take some time for those sites to catch up.We encourage vaccination sites to follow that same lead of those who are working extended hours to catch up on deliveries by scheduling more appointments to vaccinate the anxious public as quickly as possible.There are still vaccination sites closed from today’s — from the storm’s impact. Texas’s seven-day average of administered COVID-19 doses decreased by 31 percent in the past week due to winter weather impacts. Some Houston-area vaccination clinics and testing sites have now reopened. Austin Public Health does not believe reopening is safe at this time but announced that when operations resume, they will include extended hours and additional locations.Next, I want to begin to turn to our efforts to educate and communicate with the public about the importance of vaccinations. After all, today’s challenge of vaccinating those who are waiting must be accompanied by an equally aggressive effort to reach people who are considering getting vaccinated but haven’t yet decided to.We are so fortunate to have highly effective vaccines and safe vaccines, which makes the conversation with the public a much more straightforward one.So let me tell you a little bit about the three stages of our approach to communication:For the last month, we’ve been in the first stage of this work. That first stage has entailed a significant number of activities: listening to the public’s concerns, hearing from experts, testing how different audiences react to different methods of communication and different messengers, and ensuring that we can provide clear answers that the public deserves.Today, we begin a second and more public stage: engagement with key stakeholders. The COVID team has begun meeting on an ongoing basis with state and local health leaders, nonprofits, businesses, and unions about the pandemic. We’ve held more than 100 one-on-one discussions with these groups and we’ll continue this engagement throughout the response.Now, to continue to inform our efforts around vaccine confidence, over the next two weeks, the White House, along with CDC and HHS, will host a series of listening sessions with key stakeholder groups. These meetings will be led by Dr. Nunez-Smith, who is leading our equity work. These conversations will focus on how to strengthen vaccine confidence and how to eliminate barriers that underserved communities are facing to vaccinations, like paid leave, transportation, and scheduling.The meetings are kicking off today with a conversation with key leaders in the African American community. And throughout the week, we’ll be meeting with Latino groups, faith leaders, and members of the rural community.These listening sessions will continue our effort to hear directly from communities who’ve been hit hardest by this pandemic and help us build strong partnerships with those who will be key to our efforts to build vaccine confidence and reach everyone in our response.As a part of this effort, beginning today through Wednesday, CDC is hosting a National Forum on Vaccines, where they’re bringing together thousands of participants from around the country — from practitioners to jurisdictions to others working on the ground — to discuss practical strategies, technical resources, and best practices for vaccination efforts.In a moment, Dr. Walensky will discuss this.All of that continues our work on not only a whole-of-government response, but to leverage the best existing resources outside of government to end this pandemic as quickly as possible.And our third phase — the public education campaign — will be timed for maximum effectiveness and designed based on both our learnings and take full advantage of the participation of many throughout the country.So with that update, I will turn it over to Dr. Walensky and then, from there, to Dr. Fauci. And then we’ll take your questions.DR. WALENSKY: Thank you, Andy. I’m glad to be back with you today. We continue to see trends head in the right direction, but cases, hospital admissions, and deaths remain at very high levels.COVID-19 in the United States has been declining for five weeks, with the seven-day average dropping 74 percent since the peak seven-day average on January 11th. The current seven-day average — approximately 66,000 cases per day — is similar to that seen during last summer’s peak: Cases remain significantly elevated.And the seven-day average for new hospital admissions — 6,500 a day — reflects a 60 percent decline since the peak seven-day average on January 9th, the lowest seven-day average in new hospital admissions since last fall.The number of reported deaths also continues to decline, with the seven-day average slightly more than 1,900 deaths, dropping 39 percent compared to the prior seven-day average. This is the lowest since the beginning of December. However, this seven-day average is counterbalanced by the stark reality that this week we will surpass one half million COVID-19 deaths in the United States — a truly tragic reminder of the enormity of this pandemic and the loss it has afflicted on our personal lives and our communities.While the pandemic is heading in the right direction, there is still much work to do. One area that is particularly important is getting students back to in-person instructing — instruction, while protecting teachers, students, and staff.A little more than a week ago, we released our Operational Strategy for opening K-through-12 schools. This strategy provides the long-needed, science-based roadmap to help schools open safely and remain open for in-person instruction.Since the release of this strategy, we have been working closely with the Department of Education, public health partners, and education partners, including teachers and other school staff, to increase awareness of the guidance and to support its use in ongoing discussions and planning efforts for school reopenings. The goal is to achieve the reopening of schools safely.In addition, we continue to study COVID-19 spread in schools to identify the factors that contin- — that contribute to outbreaks and steps that can help prevent spread in schools. Today, CDC published a concerning report in the Morbidity and Mortality Weekly Report that details an investigation of COVID-19 spread in eight public elementary schools in a single school district in Georgia during a period of high community spread.In the report, researchers identified nine clusters of COVID-19 cases involving 13 educators and 32 students of at least six elementary schools. In two of these clusters, COVID-19 was spread first from educator to educator, and then from educator to student. These two clusters accounted for half of all the school-associated cases.Across the nine clusters, educators played an important role in the spread of COVID-19 in the schools. COVID-19 spread often occurred during in-person meetings or lunches and then subsequent spread in classrooms. COVID-19 was also spread from student to educator and from student to student, but this occurred less frequently.The two main reasons for the spread of COVID-19 in these schools were inadequate physical distancing and mask adherence. In the schools, physical distancing of at least six feet was not possible because of the high number of students in class, as well as because of classroom layouts. In addition, COVID-19 may have spread among educators and students during small group discussions where educators were in close proximity to students.Although the school district mandated in-classroom mask wearing except while eating and mask wearing was reportedly high, the study found that there were instances where lack or inadequate mask wearing by students occurred. In these situations, lack of physical distancing likely increased the risk of spread. In addition, students ate lunch in their classrooms, which may have also contributed to spread.These findings underscore the importance of strict mask adherence to the five key layered mitigation strategies outlined in the CDC’s K-12 Operational Strategy. In particular, universal mask wearing, physical distancing of at least six feet, and using cohorting or podding of students are important to minimize spread throughout the school environment. This is especially true for schools that have high rates of COVID-19 in their community. As we have noted, distancing requirements, which we recognize are very challenging, can be relaxed as school — as community rates come down.It’s also worth noting that approximately 60 percent of close contacts of the cases agreed to be tested for COVID-19. And for those who weren’t tested, testing took five to seven days — a delay that makes it incredibly difficult to rapidly contain spread.These findings highlight an additional key mitigation strategy recommended in CDC’s school guidance: the need for diagnostic testing, and rapid and efficient contact tracing, in combination with isolation and quarantine, in collaboration with the health department.The findings also highlight the importance of scaling up vaccination efforts across the country, including the continued need to prioritize teachers and other school staff for vaccination as part of the frontline essential workers, consistent with the recommendation of the Advisory Committee on Immunization Practices.CDC’s Operational Strategy specifically includes vaccination for teachers and school staff as an additional layer of protection that can be added to the five key layered mitigation strategies.Finally, I want to emphasize that while CDC’s Operational Strategy does provide for in-person instruction during all levels of community spread, the safest and quickest way to open schools and keep them open is to have as little COVID-19 in the community as possible. Enabling schools to open and remain open is therefore a shared responsibility.Encouragingly, consistent with the recent declines in COVID-19 cases in the United States, the percentage of counties with the highest level of COVID-19 transmission continued to drop, declining from approximately 90 percent, when we released our school guidance about 10 days ago, to 60 percent, as of yesterday. Now, approximately 18 percent of counties have COVID-19 levels at the low or moderate levels with — that’s consistent with full in-person learning for all K-12 schools in CDC’s guidance. And 22 percent are at the substantial level, consistent with hybrid learning or reduced in-person attendance for all K-12 schools.For the 60 percent of counties that remain in the red zone — the counties with high transmission — we encourage at least the K-5 students to return to school in hybrid or reduced in-person attendance, and for middle and high school schools virtually only — unless they can strictly implement mitigation measures and have few cases. Schools that are already open should continue to provide in-person instruction, as long as cases are low and they strictly use mitigation measures to keep them low.I hope these findings serve as a catalyst to each of us to continue to do our part to drive down the number of cases and reduce the spread of COVID-19. I know this is not easy, and so many of us are frustrated with the disruption the pandemic has had on our lives and our children’s education. But working together as a nation, we can turn the tide.Finally, I want to share some news about our virtual National Vaccine Forum that kicked off this morning. I’m excited to share that we have over 11,000 participants from 6,000 organizations across all 50 states, nearly all territories, and 128 tribes and tribal organizations.Over the next three days, these participants will share information and best practices on how to build trust and confidence in COVID-19 vaccines, use data to optimize vaccine implementation, and provide practical, real-world experience on how to increase vaccination capacities in our communities.I encourage each of you to watch the livestream plenary session throughout the day and get engaged in your community vaccination efforts.Before I turn to Dr. Fauci, I want to reiterate to everyone to continue to do your part to protect yourselves and each other by wearing a well-fitting mask, staying six feet apart from the people you do not live with, avoiding travel and crowds, washing your hands often, and getting vaccinated when the vaccine is available to you.And now I will turn it over to Dr. Fauci. I look forward to your questions.Dr. Fauci.DR. FAUCI: Thank you very much, Dr. Walensky. I’m going to talk for a few minutes today. I’m updating you on where we are on some selected therapeutics for COVID-19.So if we can move ahead to my first slide.In general, when one thinks of therapeutics, you think of them as therapeutics for early or moderate disease versus therapeutics for moderate-to-advanced disease.Clearly, the strategy early on is to block the replication of virus and prevent it from going from the upper airway to the lungs and other organ systems. However, we have found, through experience over the past many months, that when one gets advanced disease, the hyper or aberrant inflammatory or immunological response gives as much to the morbidity and mortality as the actual virus replication itself.And in that regard, a variety of drugs have been tested. One, such as remdesivir, has gained FDA approval. Its effect is clear but modest.hen regard to getting early intervention, monoclonal antibodies, both from Lilly and from Regeneron, have received emergency use authorization. Here again, the earlier one uses these, the better. These are as efficient and more efficient in those individuals who don’t necessarily have a good antibody response.The same can be said of convalescent plasma, which has also earned an emergency use authorization — again, because of the variability in the titer of antibody in various plasma concentra- — excuse me, plasma aliquots. The issue here is getting this as early as possible.There have been a number of trials of a variety of antivirals or other agents that are off the shelf that have not been targeted. I’ll get to targeted intervention in just a moment. And then hyperimmune globulin is also in clinical trial. And we await the results of all of these.With regard to therapeutics for advanced disease, as I mentioned, that is generally aimed at blocking an aberrant inflammatory or immunological response, as well as other pathogenic mechanisms, which are not necessarily that well understood.We have dexamethasone — a drug approved for many, many, many years — as the standard of care for advanced disease, particularly people in the hospital on respirators and/or requiring high-flow oxygen.Baricitinib and remdesivir have earned emergency use authorization, and a number of immunomodulators, including those that block a variety of cytokines and cytokine receptors, are currently in clinical trials.Can I have the next slide?The bottom line of what we need to do looking forward and the clear need in this is the development of potent antivirals directly acting on SARS-CoV-2, very similar to what was done with the highly successful drug development program for HIV, as well as for hepatitis C. And what I refer to is the future development of therapeutics will be based on the identification of vulnerable targets in the SARS-CoV-2 replication cycle and the design of drugs to inhibit these vulnerable targets. As I mentioned, we are beginning this, and this is going to be the direction of the future.I want to point out to the group that the NIH, in April, put together a Treatment Guidelines Panel that is a living document of clinicians and people involved in the care of SARS-CoV-2-infected individuals, who analyze the literature as well as the now very common pre-print literature and updated in — meaningfully, in very frequent intervals. It is a living document.As I mentioned, there are 47 voting members of this. And since this was put online in April of 2020 — easily accessible by COVID19TreatmentGuidelines.nih.gov — there have been over 11 million hits to this.The reason we feel this is important — and I want to, again, bring it to everyone’s attention — is that it is an easy way to get experienced clinicians to analyze data that’s already in the literature, as well as data that is in pre-print form, and involved in just clinical experience. It has been very advantageous to clinicians not only in the United States, but worldwide.And if I can have the next slide.Finally, I want to just bring to your attention something that the FDA has done today in having a press briefing, I believe, at 1:30.I want to bring it to your attention because although they delineated the aspects of it, I want to make sure everyone is aware of the very important work that the FDA is doing. And that is, they are guiding the medical product developers by updating their guidelines on how they address the virus variants. And the products involved that are impacted by this updated guidance are vaccines, COVID-19 tests, and therapeutics.Why is this important? It is very clear that we are faced right now, and will be in the future, with variants that are already present, and that with all of the immunologic and other pressures that are going on and the high degree of replication throughout the world, that there will be the selecting of a variety of variants.We ourselves in this country are already facing variants that are having impact, such as the UK variant. We have this — the South African variant in our nation. And we’re even having the evolution of variants within our own country.With regard to vaccines, the FDA outlines the scientific recommendations for the modification to authorized vaccines. In other words, we have vaccines that are out there that are highly efficacious.The manufacturers of these are going to want to know how they can address and modify their vaccines to address the ongoing evolution of variants. And we expect the manufacturing recommendations to remain the same. And the effectiveness is going to be determined by immunogenicity studies. In other words, likely not have to prove efficacy in a large study.The same holds true for COVID-19 test. The updated guidelines describes the FDA’s activities to better understand the public health impact on the variants and the impact on the test performances, and provide recommendations to the developers of these tests regarding the future genetic mutations and what they need to do when designing or modifying their existing tests.And finally, the same holds true for therapeutics, both drugs and biologics. The FDA will provide recommendations on the efficient approaches — how to generate data that potentially could support an EUA for monoclonal antibody products that might actually be effective against emerging variants, which obviously will be an issue because we already know particularly that the South African variant is, in fact, obviating the effect of several of the monoclonal antibodies that people have developed.And former guidances on therapeutics will also be updated to address the evolving landscape of the COVID-19 drug development, again, in the context of emerging SARS-CoV-2 variants.In summary, the FDA will give guidance to how these companies can address a problem that we know is with us already and that will be a problem in the future.I’ll stop there. And back to you, Andy.ACTING ADMINISTRATOR SLAVITT: Thank you, Dr. Fauci, Dr. Walensky.Let’s take a few questions.MODERATOR: Great. And if you haven’t raised your hand yet, you can go ahead and do that, and that’s how we can select you.First off, we’ll go to Katherine Eban at Vanity Fair.Q Thanks so much for having this briefing; it’s very helpful. My question is: What is the Biden administration’s policy for vaccinating federal employees? How are they prioritized?And a few other add-on questions. Do you know if the Biden administration’s policy contrasts with that of the Trump administration, regarding who was vaccinated when? And in the — in looking for — accounting for the missing doses of vaccine, have all of the doses that have been administered to federal employees been accounted for? Thank you.ACTING ADMINISTRATOR SLAVITT: Okay, multiple parts of that question. I’ll do my best to answer.As it respects to federal employees, what I can tell you is that the federal government is following the ACIP guidelines. And if you’d like more detail or if you have more specific detailed questions on aspects of federal employees, frontline workers, versus others, we will follow up with you and answer those questions.When you say “missing doses,” can you clarify what you’re referring to, please?Q Yeah, Dr. Walensky had spoken some time ago about vaccine doses that could not be accounted for, and there was a question of whether that was due to a lag of reporting from the states to Tiberius. And my question is: Have all of the doses that have been used for federal employees been fully accounted for? And is there somebody whose job it is to track that?ACTING ADMINISTRATOR SLAVITT: So — so, look, I — and, Dr. Walensky, you can comment after me if you’d like. But I believe what you’re referring to is a comment made some number of weeks ago, right after we arrived here. At that point in time, when we arrived here, about 46 percent of the vaccines that had been distributed to states had been administered. And so I think what Dr. Walensky was saying is: We have a whole lot of vaccines that have been delivered that need to now be administered.Now, today, that number is about 80 percent. So we were at 46 percent, and now we’re at 80 percent. And we applaud the states and the vaccinators and everyone involved in improving that effectiveness.So I don’t think — and again, I will invite Dr. Walensky to, of course, correct me if I’m wrong — that she was referring to quote, unquote, “missing vaccines”; simply that we needed to get the vaccines that had been delivered to be administered more effectively and more equitably.Dr. Walensky?DR. WALENSKY: Yeah, I don’t have much to add. I think when we came into the administration, we had to make sure we didn’t follow all the paths and where all the doses were, and I think we’ve done so, just as you commented.ACTING ADMINISTRATOR SLAVITT: Thank you. Next question.MODERATOR: Next we’ll go to Chris Megerian at Los Angeles Times.Q Hi, everyone. I was interested in your thoughts on the messaging around the vaccines. There’s a lot of conversation about how you need to keep doing the same things even after you get vaccinated — you know, like wearing a mask, not seeing your family, things like that. Do you think that’s preventing people from being more enthusiastic about getting vaccines? And may we see that change in the future?ACTING ADMINISTRATOR SLAVITT: Well, I’m going to invite both Dr. Walensky and Dr. Fauci to comment on that, and then — you know, and then I will as — I will as well, if there’s anything to add.DR. FAUCI: Yeah, I — actually, let — I’ll start — well, whatever. (Laughs.) I’ll start off and be very brief and hand it to Dr. Walensky.There are certain aspects of being vaccinated — and what that means to you personally and your own personal safety and that of your family — versus what vaccines will allow you to do in society. One relates to you, yourself, being vaccinated, and the other relates to the number of people and the relative percentage of people in society that will be vaccinated, because there will be things that you will not be able to do because the burden of virus in society will be very high, which it is right now. Even though we’re going way down on the decline that Dr. Walensky showed you, we are still at an unacceptably high baseline level with a seven-day average being quite high.So there are things, even if you’re vaccinated, that you’re not going to be able to do in society: for example, indoor dining, theaters, places where people congregate. That’s because of the safety of society. You, yourself, what you can do when you are together with another person, we are looking at that, and we’re going to try and find out very quickly what recommendations could be made about what people can do.One of the things that’s universal here that we know: that at this point in time, it is unclear whether when you get vaccinated and you might be protected from clinical disease, which is the primary endpoint of the vaccine studies, that you could conceivably be infected, have virus in your nasopharynx, and at that same time have no symptoms, which is the reason why we recommend and say you still need to wear a mask. Because if you do have virus in your nasopharynx, even though we hope that when the data comes in, it’s going to show that the virus level is quite low and you’re not transmitting it, we don’t know that now. And for that reason, we want to make sure that people continue to wear masks despite the fact that they’re vaccinated.So, Dr. Walensky, why don’t you add to that?DR. WALENSKY: Great. Thank you. I will say we’ve already started to come out with some guidance that demonstrates the difference if you’ve been vaccinated versus if you haven’t. So, for example, if you’ve been exposed and you’ve been fully vaccinated — two doses — there is no longer a need to quarantine after you’ve been exposed. So we are starting to emerge with some guidance in this area, and more will be forthcoming.I would echo exactly what Dr. Fauci said. We are working on rolling out a lot of vaccine to a lot of people, and yet we still have a lot of disease — 66,000 cases a day. So what we might be proposing, in terms of guidance, will really likely be at the individual level and not at the community level.ACTING ADMINISTRATOR SLAVITT: And let me just follow up, to make a broader point. The broader point that Dr. Fauci and Dr. Walensky both alluded to is this: The scientific team, the President — as the scientific team, including prominently Dr. Fauci and Dr. Walensky — are very much working together on those sets of recommendations. And I think it is in our interest to make sure they release information based on data, not on — to your — the tenet of your question — trying to convince the public of something that isn’t necessarily based on data. I think that you will hear that consistently from this administration.I will tell you that people are interested in taking the vaccine in large numbers for the same reason people are interested in taking the vaccine for MMR and for the flu: because they want to live. They don’t want to be sick and they don’t want to die. And that is a very important benefit that people don’t often talk about quite as much but that the public, we believe, clearly understands.So beyond that, what we’re able to do as a society — the scientific team is going to continue to study based upon prevalence, based upon vaccination levels, and based upon the data, and we’ll come out with more. And there are plenty of commentators outside of the government that are, of course, expressing their own views and their own opinions. And so I think that’s — that’s a part of the discourse, but it’s not one that this — that we are going to jump into too hastily.Next question.MODERATOR: Next, we’ll go to Erin Banco at the Daily Beast.Q Hey, there. Thanks so much for doing this. I have two questions for you all.The first question is about issues surrounding the CDC vaccination tracker. A lot of state officials that we spoke to over the past couple of weeks were dissatisfied with how their state was being reflected in that vaccine tracker. I want to know if there have been any steps to clear up that data, whether those concerns have been dealt with, and what the issue was there.ACTING ADMINISTRATOR SLAVITT: Dr. Walensky.DR. WALENSKY: Yeah, thank you for that. We are actively working on the vaccine tracker. We recognize there are challenges in rolling it out, and we are working to fix them imminently.Q Great. Thanks so much.My second question is: We hit the 500,000 mark today, or I guess late last night. Some officials and health experts have said that we are almost certainly undercounting COVID-19 deaths in this country. I wonder if any of you could speak to that and whether — or how confident you are in whether, you know, more than 500,000 people have died as a result of COVID-19 in this country. And I also haven’t seen a mortality study done yet since the pandemic began. Is that going to happen? And when that might be published? Thanks.ACTING ADMINISTRATOR SLAVITT: Dr. Walensky.DR. WALENSKY: Yeah, I mean, I think we can — even if — even if we were perfectly precise in how we defined COVID-19 early on as we were learning about the disease and we were accurate in our counting, I think we can sort of understand that there has been excess mortality from this pandemic outside of COVID-19 specifically. So people who delayed in getting medical care — many, you know, delayed in coming in.So I think that when history writes this, we will understand that the mortality related to this pandemic is far greater than the numbers that we have been counting for numerous reasons. There have been numerous mortality studies that have been done, and I’m certain there will be more forthcoming because we are continuing to accumulate mortality, unfortunately.ACTING ADMINISTRATOR SLAVITT: Okay, next question.MODERATOR: Last question will go to Maggie Fox at CNN.Q Thanks very much. Can I ask about the Johnson & Johnson vaccine? If it wins emergency use authorization, what are the plans for distributing the initial supply? Have you got a number in mind for how many doses you think you’ll have? And will they go to the states? Will they go to retail pharmacies? Will they go to some of these independent retail pharmacies? Can you talk a little bit about what your plans for that are?ACTING ADMINISTRATOR SLAVITT: So I think we’re going to wait on that until after the FDA does its work and then after the ACIP does its work, all consistent with our philosophy of letting the science go first. Once we understand what the scientific community has to say, we will then be in a position to answer, I think, the very relevant questions that we need scientists’ advice on. And again, this is the President’s directive to let science lead, and then we will rapidly follow that up with a strategy, both distribution and targeting and otherwise, that reflects that.Dr. Walensky or Dr. Fauci, is there anything you want to — you would add to that?DR. FAUCI: No, that’s precisely correct. It’s very important, because the FDA is going over the data very, very carefully. They’re meeting with their VRBPAC, and that, in the data, there may be hints about just how this would be used most appropriately and most effectively. When we find that out, then the policy of the distribution would become much more scientifically based, as Andy has said.DR. WALENSKY: And then, right on its heels will be the ACIP from the CDC to, sort of, give some guidance as to how it should be rolled out.Q Can I just follow up a bit though? Do you have any idea of how many doses there will be? The science isn’t guiding that. You know whether they’re manufacturing and where they are in that.DR. FAUCI: Yeah.ACTING ADMINISTRATOR SLAVITT: Yeah, we’re —DR. FAUCI: No, they’re — it’s — they’ve been contracted for 100 million doses, which we will hopefully get by the end of June, the beginning of July. The rollout of that — there will not be a lot of doses right on the heels of EUA, but that will accelerate as we get into the months towards the contractual arrangement of when 100 million doses will be given.ACTING ADMINISTRATOR SLAVITT: Yeah. And we’ll be speaking to that also. But, again, we’re going to wait for the FDA and the ACIP to do their work, and then I commit to you, you’ll be hearing a lot more, presuming that the EUA is granted. And we’re not, of course, going to take anything for granted, but presuming that that happens, I commit to you, you’ll be hearing a lot more about all those topics.I want to take the opportunity again to thank you for listening in to the briefing and, on this solemn day, to encourage you to watch the President’s remarks this evening with the Vice President, the First Lady, and the Second Gentleman to remember the 500,000 people that we’ve lost.And we will look forward to bringing you more information later in the week, of course. Thank you.3:46 P.M. EST /Public Release. This material comes from the originating organization and may be of a point-in-time nature, edited for clarity, style and length. View in full here. Why?Well, unlike many news organisations, we have no sponsors, no corporate or ideological interests. We don’t put up a paywall – we believe in free access to information of public interest. Media ownership in Australia is one of the most concentrated in the world (Learn more). Since the trend of consolidation is and has historically been upward, fewer and fewer individuals or organizations control increasing shares of the mass media in our country. According to independent assessment, about 98% of the media sector is held by three conglomerates. This tendency is not only totally unacceptable, but also to a degree frightening). Learn more hereWe endeavour to provide the community with real-time access to true unfiltered news firsthand from primary sources. It is a bumpy road with all sorties of difficulties. We can only achieve this goal together. Our website is open to any citizen journalists and organizations who want to contribute, publish high-quality insights or send media releases to improve public access to impartial information. You and we have the right to know, learn, read, hear what and how we deem appropriate.Your support is greatly appreciated. All donations are kept completely private and confidential.Thank you in advance!Tags:Africa, america, CDC, COVID-19 Response, EU, Europe, FDA, Georgia, Government, HIV, Kentucky, NIH, South Africa, Texas, UK, United States, White Houselast_img read more

first_imgShare Share via TwitterShare via FacebookShare via LinkedInShare via E-mail Richard Collins, professor of law at the CU-Boulder Law School, is an expert in constitutional law. He can be reached at 303-492-5493 or [email protected] Nagel is the Ira C. Rothgerber Jr. Professor of Constitutional Law at the CU-Boulder Law School and also an expert on the U.S. Supreme Court. He can be reached at 303-492-8428 or [email protected] Moss, associate professor of law at the CU-Boulder Law School, is an expert in constitutional law and the U.S. Supreme Court. He can be reached at 720-839-2920 (cell) or [email protected] Categories:AcademicsLaw & PoliticsCampus CommunityNews Headlinescenter_img Published: Nov. 14, 2011 last_img

first_img Published: Sept. 10, 2015 Share Share via TwitterShare via FacebookShare via LinkedInShare via E-mail The Classics Department at the University of Colorado Boulder will host students from across the state for Colorado Classics Day from 10 a.m. to 3 p.m. Saturday, Sept. 19, on the south lawn outside the Duane Physics building.About 200 primary, middle and high school students and teachers who share an interest in the ancient Greek and Roman worlds plan to attend. The event is designed to broaden students’ horizons on the world of classical language and culture along with its intellectual challenges and enduring relevance to the modern world.“Classics Day was born from the requests of Colorado high school Latin teachers and their organizational collective, the Colorado Classics Association,” said Jackie Elliott, associate professor of classics at CU-Boulder and coordinator for the program. “They have responded with great enthusiasm to our willingness to host the event and we are delighted to be partnering with them in this.”Elliott and CU-Boulder faculty and graduate students will host sessions showcasing various aspects of the classical world and CU-Boulder research expertise. Sessions topics include: Decipher a Roman Epitaph, Peter Hunt, classics professor; Mosaics: The Ancient Instagram, Stephanie Krause, master’s student with a concentration in the teaching of Latin; Greek in a Day, Lauri Reitzammer, assistant classics professor; Digging for the Ancient Past, Sarah James, assistant classics professor; Write Like Achilles! (Linear B), Dimitri Nakassis, of the University of Toronto and visiting scholar in CU-Boulder’s Classics Department; Comics and Ancient Rome, Wesley Wood, master’s student; Animals in the Ancient World: Collections in the CU Museums, Beth Dusinberre, classics professor.The event will also feature the popular Rocky Mountain Romans who wear era clothing and will show artifacts and demonstrate ancient commands and combat techniques.Teachers or schools interested in attending Classics Day should contact Elliott at [email protected] in advance. Please include the number of interested participants, school name and location. Space is limited, but everyone is welcome.Colorado Classics Day is supported by a CU-Boulder Outreach and Engagement Award and the Classics Department.In case of inclement weather, the event will be held in room 1B50 in Eaton Humanities.Contact: Jackie Elliott, [email protected] Hannah Fletcher, Outreach and Engagement, [email protected] Julie Poppen, CU-Boulder media relations, (M) 720-503-4922, (O) [email protected] “Classics Day was born from the requests of Colorado high school Latin teachers and their organizational collective, the Colorado Classics Association,” said Jackie Elliott, associate professor of classics at CU-Boulder and coordinator for the program. “They have responded with great enthusiasm to our willingness to host the event and we are delighted to be partnering with them in this.” Categories:Arts & HumanitiesGetting InvolvedNews HeadlinesCampus Communitylast_img read more

first_img Published: April 19, 2018 • By Lisa Marshall Share Share via TwitterShare via FacebookShare via LinkedInShare via E-mail A novel antioxidant studied by CU Boulder researchers targets mitochondria, pictured above, to reverse vascular aging. Categories:Health & SocietyNews Headlines Older adults who take a novel antioxidant that specifically targets cellular powerhouses, or mitochondria, see aging of their blood vessels reverse by the equivalent of 15 to 20 years within six weeks, according to new CU Boulder research.The study, published this week in the American Heart Association journal Hypertension, adds to a growing body of evidence suggesting pharmaceutical-grade nutritional supplements, or nutraceuticals, could play an important role in preventing heart disease—the nation’s No. 1 killer. It also resurrects the notion that oral antioxidants, which have been broadly dismissed as ineffective in recent years, could reap measurable health benefits if properly targeted, the authors say.“This is the first clinical trial to assess the impact of a mitochondrial-specific antioxidant on vascular function in humans,” said lead author Matthew Rossman, a postdoctoral researcher in the department of integrative physiology. “It suggests that therapies like this may hold real promise for reducing the risk of age-related cardiovascular disease.”Key takeawaysOlder adults who take a novel antioxidant see aging of their blood vessels reverse by the equivalent of 15 to 20 years.When taking the supplement, subjects saw a key measure of vascular health improve by 42 percent.The study suggests targeting mitochondria with antioxidants may be an effective way of combatting cardiovascular aging.For the study, Rossman and senior author Doug Seals, director of the Integrative Physiology of Aging Laboratory, recruited 20 healthy men and women age 60 to 79 from the Boulder area.Half took 20 milligrams per day of a commercially available supplement called MitoQ. It’s made by chemically altering the naturally-occurring antioxidant Coenzyme Q10 to make it cling to mitochondria inside cells. The other half took a placebo.After six weeks, researchers assessed how well the lining of blood vessels, or the endothelium, functioned, by measuring how much subjects’ arteries dilated with increased blood flow.Then, after a two-week “wash out” period of taking nothing, the two groups switched, with the placebo group taking the supplement, and vice versa. The tests were repeated.The researchers found that when taking the supplement, dilation of subjects’ arteries improved by 42 percent, making their blood vessels, at least by that measure, look like those of someone 15 to 20 years younger. An improvement of that magnitude, if sustained, is associated with about a 13 percent reduction in heart disease, Rossman said. The study also showed that the improvement in dilation was due to a reduction in oxidative stress.In participants who, under placebo conditions, had stiffer arteries—another indication of vascular dysfunction—supplementation was associated with reduced stiffness.A previous study conducted in the Seals laboratory in mice showed similar results.“In old mice it reversed the age-related changes in their vascular function and made it look like they had the arteries of young mice,” said Seals.Shedding new light on antioxidantsBlood vessels grow stiff and have trouble dilating with age largely as a result of oxidative stress, the excess production of metabolic byproducts called free radicals which can damage the endothelium and impair its function. When we’re young, our bodies produce enough antioxidants to quench those free radicals. But with age, the balance tips, as mitochondria and other cellular processes produce excess free radicals and the body’s antioxidant defenses can’t keep up, Rossman said. Oral antioxidant supplements like vitamin C and vitamin E fell out of favor after several large studies showed them to be ineffective. “This study breathes new life into the discredited theory that supplementing the diet with antioxidants can improve health,” said Seals. “It suggests that targeting a specific source—mitochondria—may be a better way to reduce oxidative stress and improve cardiovascular health with aging.” The study was funded by the National Institutes of Health. MitoQ Limited provided supplements and some financial support. This summer, Rossman and Seals plan to launch a three-month follow-up study to confirm the findings in a larger number of subjects and look more closely at the impact the compound has on mitochondria.The same lab published another study recently, showing that a different compound called nicotinamide riboside may also be able to reverse vascular aging in healthy subjects.“Exercise and eating a healthy diet are the most well-established approaches for maintaining cardiovascular health,” said Seals, a professor of integrative physiology. “But the reality is, at the public health level, not enough people are willing to do that. We’re looking for complementary, evidence-based options to prevent the age-related changes that drive disease. These supplements may be among them.”last_img read more